Bac3Gel and the EIC Accelerator: Growing Microbes in Fake Mucus

Bac3Gel, based in Porto Salvo near Lisbon, makes three-dimensional gels that mimic human mucus, with built-in gradients of oxygen, nutrients and firmness, so that laboratories can grow the complex communities of microbes that live in the gut and other mucous membranes. It was selected in the EIC Accelerator's January 2023 cut-off and received an EU grant of €1.50 million for a €2.14 million project, "New generation of substrates to harness the full power of microorganisms", that ran from July 2023 to October 2025, according to CORDIS. The main objective was to take the technology "from a laboratory-validated concept into market-ready products".

The project is closed. Its final report states that the platform, sold as Gut3Gel, sustained "up to approximately 90% of bacterial species present in the original inocula", was validated in several industrial testbeds, reached "market penetration", and was developed into ready-to-use formats that stay sterile and functional for up to nine months, according to the CORDIS reporting page. The report withholds customer details to preserve "confidentiality of partner-specific data".

Where Bac3Gel Stands Now

The company's website lists gels for the gut, lungs, stomach and vagina, a general bacterial gel and bead-based "growth boosters", and says it is also funded by Portugal's Recovery and Resilience Plan. A 2026 study in the journal MicrobiologyOpen, involving Bac3Gel researchers, described its Universal-Bac3Gel as supporting the growth and biofilm formation of the ESKAPE group of pathogens. Its company register entry records a capital increase in February 2026, according to Racius; the financial accounts sit behind a paywall.

The Technology: Recreating the Body's Linings

Many microbes that live in mucus cannot be grown in standard lab dishes, which offer uniform conditions. Bac3Gel's gels reproduce the gradients found in the body so that bacteria needing oxygen and those that cannot tolerate it can grow side by side. The company says its gels responded to dietary fibres and other compounds in ways consistent with clinical studies, positioning them as a partial alternative to animal testing.

What the EIC Award Promised, and What the Record Shows

The award promised market-ready products from a lab concept. The final report and the company's product range show that happened. What cannot be checked is how widely the products are used: the report cites industrial validation and customer feedback but names no customers and gives no sales.

1. Market-ready productDeliveredGut3Gel on sale.
2. Industrial validationDeliveredSeveral testbeds, unnamed.
3. Scalable formatsDeliveredBeads, 9-month shelf life.
4. Market tractionUnverifiedNo sales disclosed.

The Money

The EU paid 70% of the EIC project. Bac3Gel also receives EU money as a participant in the SurfEx project, €243,403 according to CORDIS, and is an associated partner in TOP-GUT. The size of its February 2026 capital increase and its revenue could not be checked from free sources.

What Cannot Be Checked

Why Europe Should Care

The final report ties Bac3Gel's work to European priorities on New Approach Methodologies and reducing animal experiments. Better lab models of the human microbiome could speed up research on food, supplements and drugs. A small Portuguese company has built one, with EU support at several stages.

The Verdict

Bac3Gel and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.